Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. (symbol: TARA) is a clinical-stage biopharmaceutical company specializing in identifying and advancing transformative therapies for individuals afflicted with rare and specialty diseases. Headquartered in New York, New York, the company’s mission is to discover, develop, and deliver breakthrough treatments for patients who have limited therapeutic options.
Protara’s leading program is TARA-002, an investigational cell therapy designed for the treatment of lymphatic malformations (LMs), a condition characterized by fluid-filled cysts. In a significant advancement for the company, TARA-002 has been granted the Rare Pediatric Disease designation by the U.S. Food and Drug Administration (FDA), spotlighting its potential impact on pediatric patients.
Another key asset in Protara’s pipeline is the development of intravenous (IV) choline chloride, a phospholipid substrate replacement therapy aimed at treating Intestinal Failure-Associated Liver Disease (IFALD). This investigational therapy underscores the company's commitment to addressing critical needs in the realm of pediatric and adult rare diseases.
The company's history dates back to its former identity as Artara Therapeutics, Inc. The name change to Protara Therapeutics, Inc. occurred in May 2020, reflecting a refreshed vision and strategic direction.
Protara’s forward-looking strategies are built upon solid research and development foundations, extensive clinical trial engagements, and meaningful partnerships. With recent financial updates, the company has ensured that its cash reserves, bolstered by anticipated net proceeds, can sustain its strategic plans into 2026. This financial planning provides a stable runway for Protara to continue its pioneering work and achieve significant milestones.
The company is actively involved in various clinical trials and regulatory interactions, aiming to bring its innovative therapies to market. Protara’s operational transparency and forward-looking statements indicate a robust business strategy focused on long-term growth and patient success.
For the latest updates on Protara Therapeutics, including performance, events, and developments, visit Protara Therapeutics or contact their offices directly at Justine O'Malley, Justine.OMalley@protaratx.com, 646-817-2836.
Protara Therapeutics, Inc. (Nasdaq: TARA) has announced participation in two upcoming virtual investor conferences in December 2020. The events include the Piper Sandler 32nd Annual Virtual Healthcare Conference and the Evercore ISI 3rd Annual HealthCONx Virtual Conference, where Protara will present on December 3, 2020, at 12:10 PM ET. A live webcast of the Evercore presentation will be available on the company's website, and a replay of the Piper fireside chat is currently accessible. Protara is focused on transformative therapies for cancer and rare diseases.
Protara Therapeutics (TARA) reported third-quarter 2020 results, highlighting a strong cash position of $166M as of September 30, and a net loss of $8M, compared to $2.4M in Q3 2019. The company confirmed initial comparability between TARA-002 and OK-432, with plans to complete GMP batch runs by mid-2021. Protara is set to initiate a Phase 1 trial for TARA-002 in non-muscle invasive bladder cancer in 2021 and has requested an FDA meeting to discuss the regulatory path for TARA-002 in lymphatic malformations. R&D expenses surged to $2.8M, with general and administrative costs reaching $5.3M.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced that CEO Jesse Shefferman will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 1:45 PM ET. A webcast of the presentation will be available on the Company’s website and archived for 90 days. Protara focuses on developing transformative therapies for cancer and rare diseases, including TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease. For more details, visit www.protaratx.com.
Protara Therapeutics (Nasdaq: TARA) has issued inducement non-qualified stock options for 5,200 shares to two new employees. The exercise price is set at $17.84, the closing price on November 2, 2020. Vesting occurs over four years, with 25% vesting after one year and the remainder monthly over 36 months, contingent upon continued employment. This grant complies with NASDAQ Listing Rule 5635(c)(4). Protara focuses on innovative therapies for cancer and rare diseases, including TARA-002 for bladder cancer and IV Choline Chloride for liver disease.
Protara Therapeutics (Nasdaq: TARA) announced the pricing of two underwritten public offerings, totaling 4,600,000 shares of common stock at $16.87 each and 4,148 shares of non-voting Series 1 Convertible Preferred Stock priced at $16,873.54 each, expected to close on September 24, 2020. The company anticipates receiving $147.6 million in gross proceeds, primarily for development activities associated with its lead therapy, TARA-002, targeting non-muscle invasive bladder cancer and lymphatic malformations. The offerings are conducted under an effective shelf registration statement.
Protara Therapeutics (Nasdaq: TARA) announced advancements in the clinical development of its lead therapy, TARA-002, for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations. Following constructive discussions with the FDA, initial comparability between TARA-002 and OK-432 has been confirmed, with further GMP runs planned for mid-2021. A Phase 1 study for NMIBC is set for 2021, with Phase 2 anticipated in 2022. The company will also seek a meeting with the FDA regarding TARA-002’s BLA for lymphatic malformations, supported by positive historical data from OK-432.
Protara Therapeutics (Nasdaq: TARA) announced the granting of 27,500 inducement stock options to two new employees, priced at $20.51 per share, the closing price on September 1, 2020. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter. This approval aligns with NASDAQ Listing Rule 5635(c)(4). Protara focuses on developing treatments for rare diseases, including its lead program TARA-002 for lymphatic malformations and IV Choline Chloride for IFALD.
Protara Therapeutics (Nasdaq: TARA) announced FDA's Rare Pediatric Disease designation for TARA-002, aimed at treating Lymphatic Malformations (LMs), which are rare congenital conditions. TARA-002 is a cell-based therapy utilizing the immunopotentiator OK-432, already approved in Japan and Taiwan. A Phase 2 trial showed promising results, with 86% of pediatric patients displaying significant response. This designation highlights the urgent medical need for LMs treatment, and Protara is poised to explore further development steps with the FDA.
Protara Therapeutics (TARA) announced the appointment of Barry P. Flannelly, Pharm.D, to its Board of Directors, replacing Scott Braunstein, M.D. Dr. Flannelly brings over 20 years of experience in the pharmaceutical and biotech sectors, currently serving as Executive Vice President at Incyte. CEO Jesse Shefferman expressed optimism about leveraging Dr. Flannelly's expertise to advance Protara's lead program, TARA-002, aimed at treating lymphatic malformations. The transition occurs at a pivotal time for Protara as it seeks to enhance its drug development pipeline.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
What is Protara Therapeutics, Inc. known for?
Where is Protara Therapeutics, Inc. headquartered?
What is TARA-002?
What is IV choline chloride?
When did Protara Therapeutics, Inc. change its name?
What recent designation has TARA-002 received from the FDA?
How long is Protara's financial runway expected to last?
Who can I contact for more information about Protara Therapeutics?
What is the primary focus of Protara's business strategy?
Does Protara engage in clinical trials?
